The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525

BACKGROUND: Fearing increased myelotoxicity, many practitioners adjust the body surface area (BSA)-calculated doses in obese patients. Regarding temozolomide (TMZ), a prior study suggested men with a BSA >2 m(2) may experience increased toxicity; however, surprisingly, the inverse observation was...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neurooncol Pract
Päätekijät: Robins, H Ian, Eickhoff, Jens, Gilbert, Mark R, Armstrong, Terri S, Shi, Wenyin, De Groot, John F, Schultz, Christopher J, Hunter, Grant K, Valeinis, Egils, Roach, Mack, Youssef, Emad F, Souhami, Luis, Howard, Steve P, Lieberman, Frank S, Herman, James G, Zhang, Peixin, Mehta, Minesh P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899045/
https://ncbi.nlm.nih.gov/pubmed/31832217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz006
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia